Discussion about this post

User's avatar
Patricia K's avatar

John, you raise an important distinction between a failure in regulatory judgment and a failure in the integrity of the submission process. It highlights how an administrative error can create significant regulatory and reputational consequences.

One question: If a company can conclusively demonstrate that the promotional material actually disseminated was fully compliant, should the FDA distinguish between a documentation or submission-control failure and an actual patient-safety or misbranding violation when determining the appropriate enforcement action?

Ready for more?